Islet Management’s TherapeuticsMD TXMD Stock Holding History

Islet Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-30,000	Closed	-$2.37M	–	155
2020 Q3	$2.37M	Buy	+30,000	New	+$2.39M	0.16%	99

Other funds holding TXMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Islet Management's TXMD Position: Q4 2020 in Review

Islet Management sold out of TherapeuticsMD (TXMD) in Q4 2020, closing a stake of 30,000 shares — an estimated $2.37M sold.

Islet Management first reported a position in TXMD in Q3 2020 and held it in 1 quarter. The position peaked at $2.37M in Q3 2020. 159 funds tracked by Wall St. Rank hold TXMD as of Q4 2020.

Islet Management reported no remaining TherapeuticsMD position as of Q4 2020 after selling out during the quarter.
Islet Management sold 30,000 TherapeuticsMD shares in Q4 2020, an estimated $2.37M.
Islet Management first reported a position in TherapeuticsMD in Q3 2020 and held it in 1 quarter.
Islet Management's TherapeuticsMD position peaked at $2.37M in Q3 2020.
159 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2020.

Based on Islet Management's 13F filing for Q4 2020, filed 16 Feb 2021.